Condition

Tumor

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 20 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials20

Recruiting3

Common interventions23

Lead sponsors shown15

Clinical trials

20 shown

Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related DiseasesNCT07464132 · 2025-12-17

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid TumorsNCT06819215 · 2024-10-30

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac StudyNCT04075305 · 2019-02-01

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint TumorNCT06154590 · 2024-07-01

A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy SubjectsNCT05740475 · 2023-03-20

Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 InfectionNCT06006845 · 2022-12-01

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)NCT05103358 · 2022-03-10

Exercise and Tumor Blood Flow in Lymphoma And Breast Cancer Patients (EXETUMOR 3)NCT04990856 · 2021-08-10

Post Market Study to Collect Data for Software Recognizing the Anatomical Structures During Bronchoscopy.NCT04770675 · 2020-12-01

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor TypesNCT04311710 · 2020-06-25

Prospective Determination of COVID-19 Infection Rate in a Chemotherapy Unit in Mexico.NCT04567979 · 2020-06-11

High-flow Nasal Oxygen During Rigid Bronchoscopy Under General Anesthesia: a Randomized Controlled TrialNCT03892408 · 2019-04-21

Chemoradiation vs Immunotherapy and Radiation for Head and Neck CancerNCT03383094 · 2018-03-15

ACTIVE_NOT_RECRUITING

Investigation of Hemoglobin Oxygenation With Third Harmonic Generation MicroscopyNCT03619356 · 2018-02-05

Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance ImagingNCT02767609 · 2014-05-01

Radiation Therapy and Cardiac EnzymesNCT00777751 · 2008-10-06

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast CancerNCT00802945 · 2008-10-01

Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer PatientsNCT00588835 · 2008-03-01

The Impact of M1/M2 Tumor Associated Macrophage (TAM) Polarization on Cancer Progression and Prognosis PredictionNCT00690261 · 2007-09-01

Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid TumorsNCT00413322 · 2005-09-01

Common interventions

Leading sponsors

National Taiwan University Hospital 2 Aadi Bioscience, Inc. 1 Bristol-Myers Squibb 1 DR. DIANE CHISESI NFS. MD. PHD. 1 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 1 Loma Linda University 1 Loren Mell, MD 1 M.D. Anderson Cancer Center 1 Mabwell (Shanghai) Bioscience Co., Ltd. 1 Nektar Therapeutics 1 Peking Union Medical College Hospital 1 Qmed Consulting A/S 1 Radboud University Medical Center 1 The Seventh Affiliated Hospital of Sun Yat-sen University 1 Turku University Hospital 1

Trial status mix

COMPLETED9

UNKNOWN5

RECRUITING3

TERMINATED2

ACTIVE_NOT_RECRUITING1

Phase mix

PHASE15

PHASE25

NA3

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.